ES2006476A6 - Un procedimiento para obtener interleukin-2 humana - Google Patents

Un procedimiento para obtener interleukin-2 humana

Info

Publication number
ES2006476A6
ES2006476A6 ES8701394A ES8701394A ES2006476A6 ES 2006476 A6 ES2006476 A6 ES 2006476A6 ES 8701394 A ES8701394 A ES 8701394A ES 8701394 A ES8701394 A ES 8701394A ES 2006476 A6 ES2006476 A6 ES 2006476A6
Authority
ES
Spain
Prior art keywords
interleukin
human interleukin
procedure
coding
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8701394A
Other languages
English (en)
Inventor
Bryan Richard Cullen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of ES2006476A6 publication Critical patent/ES2006476A6/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

UN PROCEDIMIENTO PARA OBTENER INTERLEUKIN-2 HUMANA, QUE CONSISTE EN UN CULTIVO DE UNA CELULA DE MAMIFERO QUE CONTIENE UN VECTOR RECOMBINANTE QUE CONSTA DE UN VECTOR Y DE UNA SECUENCIA DE DNA, QUE CODIFICA LA INTERLEUKIN-2 HUMANA, Y UNA SECUENCIA DE PEPTIDOS SEÑALIZADORA, COMPRENDIENDO UN GEN QUE CODIFICA LA INTERLEUKIN-2 HUMANA Y UNA SECUENCIA DE PEPTIDOS SEÑALIZADORA EN EL CUAL LAS SECUENCIAS NO CODIFICADORAS EN 5'' DEL GEN HAN SIDO SUSTITUIDAS POR SECUENCIAS HETEROLOGAS NO CODIFICADORAS EN 5'', DE FORMA QUE EL VECTOR RECOMBINANTE ES CAPAZ DE DIRIGIR LA EXPRESION DE LA SECUENCIA DE DNA. POSTERIORMENTE SE PROCEDE A LA SEPARACION DE LA INTERLEUKIN-2 HUMANA DEL CULTIVO. LA INTERLEUKIN-2 HUMANA SE UTILIZA PARA EL TRATAMIENTO Y PREVENCION DE ENFERMEDADES.
ES8701394A 1986-05-12 1987-05-11 Un procedimiento para obtener interleukin-2 humana Expired ES2006476A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/862,082 US4992367A (en) 1986-05-12 1986-05-12 Enhanced expression of human interleukin-2 in mammalian cells

Publications (1)

Publication Number Publication Date
ES2006476A6 true ES2006476A6 (es) 1989-05-01

Family

ID=25337602

Family Applications (2)

Application Number Title Priority Date Filing Date
ES8701394A Expired ES2006476A6 (es) 1986-05-12 1987-05-11 Un procedimiento para obtener interleukin-2 humana
ES8804018A Expired - Lifetime ES2012940A6 (es) 1986-05-12 1988-12-30 Un procedimiento para la preparacion de una celula de mamifero capaz de expresar interleukin-2 humana.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES8804018A Expired - Lifetime ES2012940A6 (es) 1986-05-12 1988-12-30 Un procedimiento para la preparacion de una celula de mamifero capaz de expresar interleukin-2 humana.

Country Status (25)

Country Link
US (1) US4992367A (es)
JP (1) JPS62278994A (es)
AR (1) AR241794A1 (es)
AT (1) AT389892B (es)
AU (1) AU603576B2 (es)
BE (1) BE1000717A5 (es)
CH (1) CH675731A5 (es)
DE (1) DE3715808A1 (es)
DK (1) DK234087A (es)
ES (2) ES2006476A6 (es)
FI (1) FI872096A7 (es)
FR (1) FR2598433B1 (es)
GB (1) GB2190382B (es)
GR (1) GR870727B (es)
HU (1) HU205384B (es)
IL (1) IL82475A0 (es)
IT (1) IT1215478B (es)
LU (1) LU86874A1 (es)
MC (1) MC1821A1 (es)
NL (1) NL8701132A (es)
NO (1) NO871939L (es)
NZ (1) NZ220246A (es)
PT (1) PT84849B (es)
SE (1) SE8701934L (es)
ZA (1) ZA872768B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU633471B2 (en) * 1987-08-26 1993-02-04 Biogen Idec Ma Inc. Biological materials, processes for producing biological materials and for using such materials in therapy
FR2619719B1 (fr) * 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
FR2636231A1 (fr) * 1988-09-09 1990-03-16 Sanofi Sa Cellules eucaryotes recombinees productrices d'interleukine-1 (beta) mature n-glycosylee, procede et vecteurs necessaires pour leur obtention et procede d'obtention d'interleukine-1 (beta) mature n-glycosylee
WO1990010069A1 (fr) * 1989-02-28 1990-09-07 Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr ADN pAA 1213-23 ET pAC 262-33 DE PLASMIDE DE RECOMBINAISON CODANT POUR LA SYNTHESE D'INTERLEUKINE-2 HUMAINE, LEUR PROCEDE DE CONSTRUCTION ET SOUCHE DE BACTERIES ESCHERICHIA COLI RRI/pAC 262-33 EN TANT QUE PRODUCTEUR D'INTERLEUKINE-2 HUMAINE
IL95330A0 (en) * 1989-08-11 1991-06-30 Lilly Co Eli Expression of a functional insect specific toxin gene in mammalian cells
GB9106185D0 (en) * 1991-03-22 1991-05-08 Wellcome Found Biological control agents
US5856178A (en) * 1993-08-30 1999-01-05 Utah State University DNA cassettes for expression of lytic peptides in mammalian cells and transgenic organisms containing same
US5548075A (en) * 1993-08-30 1996-08-20 Utah State University DNA cassette and transgenic organisms carrying lytic peptide-encoding genes
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US5686246A (en) * 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
EP0855918A4 (en) 1995-10-17 2002-08-14 Univ Wayne State INTERLEUKIN-15 FROM CHICKENS AND ITS USE
US6001613A (en) * 1996-05-24 1999-12-14 Board Of Regents Of University Of Nebraska Plasmid bearing a cDNA copy of the genome of bovine viral diarrhea virus, chimeric derivatives thereof, and method of producing an infectious bovine viral diarrhea virus using said plasmid
AUPP655698A0 (en) * 1998-10-16 1998-11-05 Commonwealth Scientific And Industrial Research Organisation Delivery system for porcine somatotropin
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
KR20020043448A (ko) * 2000-12-04 2002-06-10 리송알렉스인근 인터루킨-2 재조합 단백질 및 그의 제조방법
EP2848255B1 (en) * 2001-02-20 2017-08-23 Janssen Pharmaceuticals, Inc. Artificial Drosophila antigen presenting cell for preparing CD8 cell suspension for use in the treatment of cancer
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2814039C3 (de) * 1978-03-31 1981-02-19 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf), 3300 Braunschweig Verfahren zur Herstellung von Hybrid-Bakterien
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
DE3377363D1 (en) * 1982-03-31 1988-08-18 Ajinomoto Kk Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
AU556353B2 (en) * 1982-12-15 1986-10-30 Ajinomoto Co., Inc. Interleukin-2 polypeptide
AU579089B2 (en) * 1983-02-08 1988-11-17 Biogen, Inc. Human interleukin-2-like polypeptides
IL71275A0 (en) * 1983-03-21 1984-06-29 Sparamedica Ag Human interleukin-2-and its preparation
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
GB8327880D0 (en) * 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
WO1985002200A1 (en) * 1983-11-14 1985-05-23 Chiron Corporation Interleukin-2 production using cloned genes for interleukin-2 and yeast alpha-factor
FR2559782B1 (fr) * 1984-02-16 1986-07-18 Transgene Sa Vecteur d'expression dans les levures de l'interleukine-2, levures transformees et procede de preparation de l'interleukine-2
EP0163603B1 (en) * 1984-05-08 1989-12-13 Genetics Institute, Inc. A human t-cell growth factor
DE3419995A1 (de) * 1984-05-29 1985-12-05 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von human-interleukin-2 und mittel zur durchfuehrung dieses verfahrens
EP0172619A1 (en) * 1984-06-20 1986-02-26 Takeda Chemical Industries, Ltd. Novel transformant and use thereof
CA1275954C (en) * 1984-08-31 1990-11-06 Hing Cheug Wong 3'-expression enhancing fragments and method
FR2583770B1 (fr) * 1985-06-21 1988-08-19 Transgene Sa Expression de l'il-2 humaine dans les cellules de mammiferes par un poxvirus recombine
FR2619719B1 (fr) * 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices

Also Published As

Publication number Publication date
DE3715808A1 (de) 1987-12-10
FR2598433A1 (fr) 1987-11-13
SE8701934L (sv) 1987-11-13
GR870727B (en) 1987-09-21
ES2012940A6 (es) 1990-04-16
PT84849A (pt) 1987-06-01
JPS62278994A (ja) 1987-12-03
HU205384B (en) 1992-04-28
AT389892B (de) 1990-02-12
BE1000717A5 (fr) 1989-03-21
AU603576B2 (en) 1990-11-22
MC1821A1 (fr) 1988-03-18
FR2598433B1 (fr) 1990-09-21
GB2190382A (en) 1987-11-18
NO871939D0 (no) 1987-05-11
AR241794A1 (es) 1992-12-30
US4992367A (en) 1991-02-12
NL8701132A (nl) 1987-12-01
AU7270387A (en) 1987-11-19
DK234087D0 (da) 1987-05-08
PT84849B (pt) 1990-02-08
DK234087A (da) 1987-11-13
NZ220246A (en) 1990-07-26
IL82475A0 (en) 1987-11-30
ZA872768B (en) 1988-04-27
GB8711072D0 (en) 1987-06-17
IT1215478B (it) 1990-02-14
HUT45558A (en) 1988-07-28
FI872096A7 (fi) 1987-11-13
LU86874A1 (fr) 1988-06-13
CH675731A5 (es) 1990-10-31
ATA263787A (de) 1989-07-15
GB2190382B (en) 1990-08-15
IT8720479A0 (it) 1987-05-12
FI872096A0 (fi) 1987-05-12
NO871939L (no) 1987-11-13
SE8701934D0 (sv) 1987-05-11

Similar Documents

Publication Publication Date Title
ES2006476A6 (es) Un procedimiento para obtener interleukin-2 humana
AR241654A1 (es) Procedimiento para producir activador de plasminogeno de tejido humano.
AR241314A1 (es) Aislado de adn, vector en base en dicho aislado cultivo de celulas tratadas con dicho vector y preparacion de factor viii humano funcional.
MX9206041A (es) Proceso para producir interferon inmune humano.
ES8306325A1 (es) "proceso para la produccion microbiana de interferon fibroblasto humano".
ES2127730T3 (es) Secuencias de nucleotidos que codifican una proteina humana que tiene propiedades reguladoras de la angiogenesis.
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
DE69635899D1 (de) Polypeptid, das die differenzierung unterdrueckt
ES2150916T3 (es) Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados.
ES2054638T3 (es) Gen codificante de los factores humanos de estimulacion colonial.
CY1106798T1 (el) Ανθρωπινα μεσεγχυματικα βλαστοκυτταρα απο περιφερειακο αιμα
ES8302778A1 (es) Un procedimiento para producir un polipeptido antiviral.
ES2104565T3 (es) Determinantes anti-receptor de celulas t como tratamiento de enfermedades autoinmunes.
FI924574A0 (fi) Genterapi foer cellproliferativa sjukdomar
PT87562A (pt) Procede de expression de la proapolipoproteine a-i humaine
ES2061632T5 (es) Kluyveromyces como celula hospedante.
ES2039233T5 (es) Procedimientos para la produccion de glicoproteinas del citomegalovirus humano (hcmv), anticuerpos correspondientes y vacunas del hcmv, y vectores recombinantes para los mismos.
MY102918A (en) Purified antineoplaston fractions and methods of treating neoplastic disease.
ES2062993T3 (es) Factor de crecimiento humano i semejante a la preproinsulina.
DK0666914T3 (da) Hidtil ukendt P-selectin-ligandprotein
ES8801671A1 (es) Un procedimiento para preparar relaxina humana o sus analogos
AR013529A1 (es) Rantes amino-terminalmente truncado, moleculas de adn, vector de expresion, celula huesped, proceso recombinante para prepararlo, su uso para preparar un medicamento y composicion farmaceutica que lo comprende.
ES2173856T3 (es) Proceso para la preparacion de vectores geneticos para la expresion del factor de crecimiento nervioso en celulas eucariotas.
ES2062982T3 (es) Clonaje y expresion del factor de crecimiento de fibroblasto acido.
AR029627A1 (es) Derivados de proteina c y composiciones farmaceuticas formuladas con dichos derivados, moleculas de dna recombinante que codifican dichos derivados; vectores de transformacion que comprenden dichos derivados; aislados de acidos nucleicos que comprenden polinucleotidos que codifican al menos el 90% d

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20041102